MOLOGNI LUCA
- U08, Floor: 4, Room: LABORATORIO 4.10
- U08, Floor: 4, Room: 4043
Publications
Villa, M., Malighetti, F., Sala, E., Sharma, G., Arosio, G., Gemelli, M., et al. (2024). New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients. NPJ PRECISION ONCOLOGY, 8(1) [10.1038/s41698-024-00498-w]. Detail
Crespiatico, I., Zaghi, M., Mastini, C., D'Aliberti, D., Mauri, M., Mercado, C., et al. (2024). First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. BLOOD [10.1182/blood.2023021349]. Detail
Cordani, N., Mologni, L., Piazza, R., Cogliati, V., Pepe, F., Capici, S., et al. (2023). Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells. In Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX (pp.13-21). AACR [10.1158/1538-7445.SABCS22-P1-13-21]. Detail
Fontana, D., Crespiatico, I., Crippa, V., Malighetti, F., Villa, M., Angaroni, F., et al. (2023). Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients. NATURE COMMUNICATIONS, 14(1) [10.1038/s41467-023-41670-3]. Detail
Cordani, N., Lisini, D., Coccè, V., Paglia, G., Meanti, R., Cerrito, M., et al. (2023). Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC). INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(6), 1-16 [10.3390/ijms24065864]. Detail